In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
about
Current and future antiviral therapy of severe seasonal and avian influenzaIn Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsEfficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsActivity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106Effect of T-705 treatment on western equine encephalitis in a mouse modelInhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomersTreatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirinProgress of small molecular inhibitors in the development of anti-influenza virus agents.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Drugs in development for influenza.Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesFavipiravir (T-705), a novel viral RNA polymerase inhibitor.The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors.Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c miceCharacteristics of human infection with avian influenza viruses and development of new antiviral agents.Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Identification of a broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype virus-based approach.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Mechanism of action of T-705 against influenza virus.Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistanceSensitivity of H5N1 influenza viruses to oseltamivir: an update
P2860
Q24656164-6AA3E3ED-6FB1-4721-B95D-F5102A38545EQ27481401-42C7583B-E86D-4E07-BACC-ABBEA0097C7BQ27487357-3926A49D-853D-45A9-9F87-54960118B05CQ27487527-6AB7E8BD-EB79-4386-848D-41793BA1F767Q27488864-29B7ADEB-8ACB-4149-8FB1-66ECD94349CFQ27673286-87D0E8F8-7B12-4F81-A2B2-B9530DB49941Q28474006-12EAE9E0-2BCC-47CC-B98A-77F0903E9FFCQ30234943-FB385FE3-8862-4860-8525-24C7AE58E105Q30387420-B6CF84A4-45C4-4291-B1BE-99430518560BQ30391218-3503C9A5-D990-4948-9BAE-C76F5DAF2006Q30392198-32227902-6752-442C-8B39-C4F22033CD52Q30404586-5AAEE81C-D209-447C-B86B-81F46EB650B9Q30574395-924AC658-FA99-4D75-93D7-E36BB1831FEAQ33559151-450D96B6-7A58-4BBF-8FF0-F9605A586A66Q33639979-F54FC40D-622E-480B-9A3A-CC6BA9182250Q34374652-3C0DE503-DFC1-48EF-8E0A-D6144C1D00C5Q35055899-33815D10-A2EE-4766-8FA5-883186850DAFQ35076802-1B57AECA-C9C9-400B-AF4E-A39BA02FA234Q35647695-EEF152B6-12FC-4340-B177-6A62881A6D6FQ36607954-8E1A169C-3E7D-482F-9E85-8D46FDFA3109Q37217863-C06FD0FA-C368-420D-A71B-25B4A08D6331Q37559422-331343B3-B858-4112-B348-EC08B62C8925Q38833628-98209529-9FE0-4F9A-ADF6-56EC9A035D88Q39177100-A75562B1-A2A2-4394-B310-5C512EF76288Q40044875-64264D35-9C4E-4927-8B4F-185927FE3BBAQ41091905-DEB59247-8848-4E4B-B6E7-C198299AAE4BQ42110040-FF5EB24E-2A29-4A9B-A3EF-F422F4133149Q50051418-AD7B1878-A644-4675-B159-6C85F176DFEEQ56985884-A4C1E601-DA9B-4901-B469-288C6A52F01EQ57726187-B034B3DA-1DA6-45E5-9F91-E8BD7BC7DD47
P2860
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@en
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@nl
type
label
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@en
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@nl
prefLabel
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@en
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@nl
P2093
P2860
P1476
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
@en
P2093
Hiroyuki Egawa
Kazumi Takahashi
Kimiyasu Shiraki
Kyo Kozaki
Masako Kuno
Nobuhiko Nomura
Shinzaburo Minami
Tomoko Kamiyama
Yoshiko Fukuda
Yousuke Furuta
P2860
P304
P356
10.1177/095632020301400502
P577
2003-09-01T00:00:00Z